UK-US Regulatory Partnership & Global AI Alignment

Issue 134 — Fragmentation to Collaboration

Your weekly source for medical device regulatory intelligence

📝 From the Editor

The regulatory landscape is shifting from fragmentation to collaboration.

This week brought watershed moments: the MHRA-FDA partnership signals a new era of transatlantic regulatory alignment, while the EU doubles down on AI integration across healthcare with concrete implementation strategies. Meanwhile, manufacturers face converging deadlines—ISO 13485 transition, China's UDI mandate, and MDR terminology challenges.

Don't miss:Due Diligence for MedTech Investors with Renae Franz and Dr. Mudit K. Jain (October 22nd, 11 AM ET) reveals what VCs really look for before writing checks from $5M to $100M.

This week: UK-US forge new collaboration on medical technologies and AI, EU launches AI factories across member states, and FDA's ISO 13485 transition enters final countdown.

Plus, this Friday's In-Focus guests, Dina Lakayan and Maarten ter Mors , founders of CREATE will unveil their new AI tools for regulatory affairs that aced the RAPS RAC exam!

— Sean Smith , Founder & Publisher

🎯 Quick Hits: This Week's Top LinkedIn Posts (in no special order)

• Mike B. Wetheriington shared lessons from a neurostimulator 510(k) placed on hold despite passing completeness checks—the key issue was framing data from FDA's regulatory perspective, not just engineering logic.
• Danny Van Roijen announced six new AI factories and seven antennas under the EU AI Continent Action Plan, with nine facilities targeting health and life sciences.
• Sigrid Berge van Rooijen emphasized that AI adoption in clinical workflows depends on seamless integration, sharing 10 resources to avoid common pitfalls like overlooking clinician input and neglecting data quality.
• Jianwei Li discussed optimized chromatographic methods under ISO 10993-18 for accurate extractables analysis, noting this critical topic lacks adequate coverage in standards.
• EU MDR Compliance released a visual overview of IEC 62304 software lifecycle requirements, highlighting 5 core processes and safety classes A, B, and C that determine documentation depth.
• 🔥 Maria E. Donawa, MD, examined how "similar device" appears throughout MDR but is only defined in EU guidance, creating compliance uncertainty.
• Tibor Zechmeister outlined three key concepts for starting the notified body journey: scope verification, geography/language fit, and capacity assessment to avoid year-long delays.
• Michelle Lott broke down FDA's risk-based device classes in 5 minutes, clarifying how each class determines regulatory pathway and requirements.
• Swetha Ravichandiran highlighted FDA's shift to ISO 13485 by February 2026, with previously exempt records now open to inspection.
• Beat Keller clarified that U.S. Agents handle all FDA communication and must be strategically selected as part of compliance strategy, not just a checkbox.
• Elaine Tan detailed China's NMPA UDI timelines: June 2027 for Class II and IVDs, June 2029 for Class I devices.
• Nataliya Nedkova stressed how inconsistent terminology causes delays, audit findings, and patient safety risks across regulatory submissions.
• Nelinia Varenas covered how manufacturers selling into defense, aerospace, and medical devices can turn cybersecurity and ITAR compliance into competitive advantages.

🔥 This Week's Top Story

UK-US Forge Historic Partnership on Medical Technologies and AI

The MHRA and FDA officially announced strengthened bilateral collaboration introducing concrete pathways for regulatory reciprocity—a development covered in Martin King's Regulatory Roundup this week.

The MHRA confirmed new reliance pathways for FDA-cleared devices (510(k), De Novo, PMA) designed to reduce UK time-to-market, with legislative implementation expected in 2026 and operational rollout in 2027.

The announcement coincides with the launch of MHRA's National AI Commission, which includes US experts and tech leaders from Google and Microsoft. The commission will shape transparent AI regulation supporting NHS integration and international alignment.

This partnership builds on MHRA's June 2025 regulatory overhaul and aligns with FDA's Total Product Life Cycle Advisory Program, positioning the UK as a globally competitive MedTech hub while encouraging cross-border investment.

For manufacturers, this signals greater harmonization between two of the world's largest markets, potentially reducing duplicate submissions and accelerating patient access to breakthrough technologies.

📋 Featured Updates

"Similar Device" Definition Gap Identified — A new article, by Maria E. Donawa, MD, highlights how "similar device" appears throughout MDR but is defined only in MDCG guidance, creating compliance uncertainty for clinical evaluation and post-market surveillance requirements.

EU AI Implementation Accelerates — Martin King shared the European Commission's "Apply AI" and "RAISE" initiatives shift from strategy to implementation with 12 sectoral flagships including healthcare AI screening centers. Six new AI factories and seven antennas launched across member states, nine targeting health and life sciences.

ISO 13485 Transition: 16 Months to Go — Swetha Ravichandiran highlights that February 2, 2026 marks FDA's adoption of ISO 13485:2016 via QMSR. Previously exempt records (internal audits, supplier audits, management reviews) now open to inspection. Companies must conduct gap analysis, review documentation practices, and train quality teams immediately.

China's UDI Mandate Timeline Confirmed — Elaine T. detailed NMPA draft timelines establishing mandatory UDI: effective immediately for Class III/high-risk Class II; June 2027 for Class II and Class I IVDs; June 2029 for Class I. Foreign manufacturers should align strategy and select UDI issuing entity now.

📅 Featured Webinar

Due Diligence for MedTech InvestorsOctober 22, 2025 • 11:00 AM ET • Virtual

Learn how top venture firms evaluate MedTech opportunities from Dr. Mudit K. Jain (Founder, Treo Ventures—hundreds of millions invested, multiple exits) and Renae Franz (leanRAQA). They'll reveal what separates fundable teams from fragile ones, how investment strategies shift between $5M and $100M raises, and the practical due-diligence checklist VCs actually use to spot red flags before they write checks.

Register Now • Recording and slides available to all registrants

📅 Upcoming Events

Due Diligence for MedTech Investors October 22, 2025 • 11:00 AM ET • Virtual Renae Franz of leanRAQA demystifies due diligence for MedTech investments, covering regulatory red flags, quality system assessment, and strategic evaluation frameworks.

TEAM-PRRC Annual Summit — October 23-24, 2025 • Rome, Italy • SOLD OUT! 100 attendees, featuring MedTech Europe, Italian authorities, and roundtables with 5 notified bodies.

Initiating MedTech Pre-Market Clinical Studies — October 29, 2025 • Virtual • Daniela Karrer and Matteo Mosso (Donawa Lifescience) on EU clinical study requirements from protocol design through submission. MLV Webinar, registration coming soon!

2025 MedTech Startup Symposium — November 5, 2025 • Philadelphia, PA • In-person event for early-stage companies. RSVP Required

MedTech Malta Summit 2025 — November 12-14, 2025 • Valletta, Malta • 2,000+ attendees, StartUp Pitch competition, Awards gala. Early Bird Registration

eIFU and Labeling Panel Discussion — November 30, 2025 • Virtual • AKRA TEAM expert panel on electronic IFU requirements across global markets. MLV Webinar, registration coming soon!

💭 Weekly Reflections

From Marcus Engineering's 510(k) Roundup (October 13, 2025)

64 total clearancesacross 17 categories | 140 days average review time | 7 first-time recipients 🚀

This week's standouts:

• 🚀 THINK Surgical – TMINI Miniature Robotic System — Handheld robot for knee surgery that works with multiple implant brands
• Roche Diagnostics – Elecsys® pTau-181 Plasma — Blood test for Alzheimer's that replaces spinal taps and brain scans
• PROCEPT BioRobotics – HYDROS™ — AI-powered robotic system for prostate treatment using water and imaging
• Review time range: 21 days (Roche immunology test) to 375 days (Osseofuse dental implant)
• Marcus's take: "Simple on the surface, brilliant underneath. Just the kind of devices we love to see."

From Martin King's Regulatory Roundup

October 13, 2025 Issue

• EU: "Apply AI" & "AI in Science (RAISE)" implementation; 51 MDR / 18 IVDR notified bodies (1 IVDR withdrawal); EDQM introduces EG/DEG detection method post-contamination cases
• EMA: EU-US MRA expansion; DARWIN EU® now 180M patients; 5,000+ CTIS trials; new nitrosamines Q&A; ICH M14 (RWD Safety); SmPC paediatric training
• National:HPRA (Ireland) — 2026 fees +2.5%, AI/NIS2 focus | MHRA (UK) — GB-only studies clarified, FDA collaboration, 60-day device review, SME easements | Swissmedic — Updated forms | TGA (Australia) — Nitrosamine & CDSS guidance, EU MDR transition service | Hong Kong — Voluntary MD listing pathway
• Global: IMDRF PCCP consultation on adaptive SaMD; WHO launches Global Clinical Trials Forum

🎯 The Bottom Line

This week crystallizes a fundamental shift: from parallel national systems to coordinated international frameworks.

The MHRA-FDA partnership + EU AI infrastructure + China's UDI mandate = regulators building interoperable systems that reduce friction while maintaining safety standards.

Three strategic imperatives:

1. Leverage regulatory reciprocity — New UK reliance pathways for FDA-cleared devices create multi-market acceleration opportunities
2. Prepare for quality convergence — ISO 13485 adoption exposes previously exempt records to inspection (16 months to deadline)
3. Anticipate AI regulation — Transparent, explainable architectures will have regulatory advantages over "black box" systems

Your action items:

• Assess MHRA-FDA reliance pathways for your portfolio
• Conduct ISO 13485 gap analysis before February 2026
• Review AI/software architecture for transparency requirements
• Evaluate China strategy against new UDI timelines
• Clarify "similar device" interpretations in clinical evaluations

The winners won't be companies that merely comply—they'll be those that architect regulatory strategy as competitive advantage.

Have insights to share? Reply to contribute to next week's issue.

—Sean

#MedicalDevices #RegulatoryAffairs #QualityAssurance #ISO13485 #MHRA #FDA #NMPA #AI #MedTech #510k